There are currently 167 clinical trials in Boca Raton, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Boca Raton Regional Hospital, Parkinson's Disease and Movement Disorders Center of Boca Raton, GSK Investigational Site and Excel Medical Clinical Trials. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/22/2024
Locations: Neurology Offices of South Florida, Boca Raton, Florida +1 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796
Recruiting
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Boca Raton Regional Hospital, Boca Raton, Florida
Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Boca Raton Regional Hospital, Boca Raton, Florida
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051
Recruiting
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: SFM Clinical Research, LLC, Boca Raton, Florida
Conditions: Myasthenia Gravis, Generalized
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin al... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/22/2024
Locations: Research Site, Boca Raton, Florida
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
05/20/2024
Locations: ENT and Allergy Associates of Florida, LLC, Boca Raton, Florida
Conditions: Sleep Apnea, Obstructive
Register for Updates
Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis
NCT06121882
Recruiting
The goal of this clinical trial is to examine the effect of a single autologous, intra-articular injection of MFat versus saline injection for the treatment of pain and function associated with K/L grade 2/3 knee Osteoarthritis. Participants will receive an injection of MFat or saline.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Baptist Health South Florida, Inc., Boca Raton, Florida
Conditions: Knee Osteoarthritis, Osteo Arthritis Knee
Register for Updates
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NCT05283226
Recruiting
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Lynn Cancer Center, Boca Raton, Florida
Conditions: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Register for Updates
Digital Detection of Dementia (D Cubed) Studies: D3
NCT06224205
Recruiting
The specific aim of the pragmatic trial is to evaluate the practical utility and effect of the PDM, the QDRS, and the combined approach (PDM + QDRS) in improving the annual rate of new documented ADRD diagnosis in primary care practices.
Gender:
All
Ages:
65 years and above
Trial Updated:
05/16/2024
Locations: University of Miami School of Medicine, Boca Raton, Florida
Conditions: Alzheimer Disease and Related Dementias (ADRD)
Register for Updates
Natural History Study in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
NCT05020743
Recruiting
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare, rapidly progressing, genetic, neurodegenerative disease for which no definitive treatment options and limited information on the natural history of the disease are available. The structural, genetic, and neuropathophysiological abnormalities of ALSP lead to the onset of neurologic symptoms, such as moderate to severe motor and neuropsychiatric impairments. This natural history study will collect data to co... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Investigative Site 1, Boca Raton, Florida
Conditions: ALSP
Register for Updates
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
NCT05836220
Recruiting
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2024
Locations: Site Number: USA041-2, Boca Raton, Florida
Conditions: Secondary Hyperparathyroidism, End Stage Kidney Disease
Register for Updates
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100
Recruiting
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: GenesisCare - Boca Raton, Boca Raton, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates